

3 December 2024

BELLUSCURA PLC
("Belluscura" or the "Company" or "Group")

New Wound Care Joint Venture

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Company has entered into a product development joint venture with its research partner Separation Design Group and a major medical device company to explore the use of oxygen-based wound care solutions.

Belluscura will serve as the original equipment manufacturer (OEM), while the major medical device company will fund product development, clinical trials, and distribution upon regulatory approval, with an initial clinical study scheduled to begin in early Q2 2025, outside the United States.

The joint venture will focus on innovative oxygen-based solutions for the wound care market, leveraging Belluscura's expertise in oxygen technology. In particular, it will focus on developments in continuously diffused oxygen (CDO) therapy, a topical oxygen delivery method designed to accelerate wound healing by providing pure oxygen directly to the wound. CDO therapy has demonstrated promise in treating chronic or hard-to-heal wounds, including diabetic foot ulcers.

The wound care market, valued at 22.5 billion in 2023, is projected to grow at a robust 5.9% CAGR through to 2032, according to a Global Markets Insights report published in 2023¹, and Belluscura's technology and expertise positions it well to capitalise on this significant market opportunity.

Commenting, Bob Rauker, Chief Executive said:

"Our joint venture with Separation Design Group demonstrates the potential of leveraging our oxygen-based technology across broader therapeutic applications and healthcare challenges, such as addressing an unmet need in the hard-to-heal wounds market, which is valued at over 22 billion today and growing.

"Partnering with a globally recognized medical device company enables us to explore the development and commercialization of this innovative wound care solution by combining our oxygen enrichment technology and expertise with their resources and distribution capabilities."

-Ends-

¹ *Wound Care Market - Product (Advanced Wound Dressing, Surgical Wound Care, Traditional Wound Care, Wound Therapy Devices, Wound Care Biologics), Application (Chronic, Acute), End use - Global Forecast, 2023-2032*

For further information please contact:

Belluscura plc
Adam Reynolds, Chairman
Robert Rauker, CEO
Simon Neicheril, Chief Financial Officer

Tel: +44 (0)20 3128 8100

SPARK Advisory Partners Limited
Nominated Adviser
Neil Baldwin / Jade Bayat

Tel: +44 (0)20 3368 3550

Dowgate Capital Limited
Broker
Russell Cook / Nicholas Chambers

Tel: +44 (0)20 3903 7715

MHP

Financial PR & Investor Relations

Katie Hunt/Matthew Taylor

Tel: +44 (0)20 3128 8100

email: [Belluscura@mhpgroup.com](mailto:belluscura@mhpgroup.com)

About Belluscura plc (<https://ir.belluscura.com/>)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFSFFWEELSEIE